CDKN1A and neuroblastoma: In MYCN-amplified neuroblastoma MYCN transactivates miR-17-5p, which in turn accelerates cell cycle progression by downmodulating p21 and protects cells from apoptosis by inhibiting BIM expression (Figure 7).